Acromegaly Treatment Goals:
For you, blocking GH action to help achieve IGF-I control 7
For your patient, overall symptom improvement1
Consider your goal of controlling acromegaly, and your patients' desire for relief from disease signs and symptoms. SOMAVERT® has been shown to block growth hormone action, normalize IGF-I levels, and improve the overall signs and symptoms of acromegaly (soft-tissue swelling, arthralgia, headache, perspiration and fatigue) in a majority of patients in clinical trials.1 Take a look to learn about SOMAVERT and:
SOMAVERT (pegvisomant for injection) is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum IGF-I levels.
Important Safety Information for SOMAVERT
SOMAVERT is contraindicated in patients with a history of hypersensitivity to any of its components.
Patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids.
Functional effects of increased GH are prevented by GH receptor blockade; therefore, patients on SOMAVERT should be carefully observed for the clinical signs and symptoms of a GH-deficient state.
Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT.
Important safety information regarding periodic tumor size monitoring
Tumors that secrete GH may expand and cause serious complications. All patients with GH-secreting tumors, including those receiving SOMAVERT, should be carefully monitored for changes in tumor volume. Overall, mean tumor size was unchanged during the course of treatment in clinical studies. Tumor volume change did not appear to be influenced by whether or not patients had previously received radiation therapy.
Important safety information regarding liver test monitoring
Monitor liver tests based on baseline values and changes during therapy according to the schedule in the full prescribing information. In clinical studies with SOMAVERT, ALT was >3X but <10X the upper limit of normal (ULN) in patients treated with SOMAVERT (1.2%) vs placebo (2.1%). ALT and AST elevations occurred within 4 to 12 weeks after the start of therapy and did not appear to be related to the dose. 2 patients (0.8%) experienced elevations of ALT and AST serum concentrations >10X the upper limit of normal (ULN). In both patients, the elevations normalized after discontinuation of the medicine. If a patient develops liver test elevations, or any other symptoms of liver dysfunction while receiving SOMAVERT, please see Liver Tests section of full Prescribing Information.
In subjects with systemic hypersensitivity reactions, caution and close monitoring should be exercised when re-initiating SOMAVERT therapy.
The most common adverse events (>10% and at frequencies greater than placebo) in 1 of the 3 active treatment arms in a 12-week placebo-controlled study (N=112) included infection, pain, diarrhea, nausea, flu syndrome, abnormal liver function tests, and injection-site reaction.
Injection sites should be rotated daily to help prevent lipohypertrophy.
The maximum indicated daily maintenance dose for SOMAVERT is 30 mg.